Mold-Tek Packaging shares closed lower on Tuesday following the announcement of the packaging company's financial results for the first quarter of the 2026-27 financial year. During the quarter, the company's revenue from operations increased by 24.9% on an annual basis, reaching Rs 300 crore.
Stock Market Performance and Valuation
The company's stock closed 4.6% lower at Rs 659.85 per share on BSE on Tuesday, registering a market capitalisation of Rs 2,192.94 crore. Throughout the trading session, the stock hit an intraday low of Rs 644.35 per share and touched an intraday high of Rs 699.85 per share. Looking at its broader yearly performance, the stock touched its 52-week high mark of Rs 890 per share on July 30, 2025, while it dipped to a 52-week low of Rs 453.80 per share on March 30, 2026. The company maintains a return on equity of 12.19%, though its share price has declined by around 4.34% over the past month and roughly 15.43% over the last three months.
Profit After Tax and Sales Growth
The company's profit after tax surged by 14.2% to Rs 35.57 crore in the first quarter of the 2026-27 financial year, compared to Rs 22.4 crore recorded during the same period in the previous year. Furthermore, Mold-Tek's net sales grew by 26.32% on a year-on-year basis. This upward movement was largely driven by robust demand across all operational business segments. Enhanced operational efficiency and rigorous cost management also helped push the company's EBITDA up by 17.31%. Additionally, overall sales volume recorded a 5.82% annual growth during the quarter under review.
Segment-Wise Performance Breakdown
A closer look at the departmental breakdown reveals that the company's pharma packs posted a strong 38.75% sales volume growth. Meanwhile, the food and FMCG packet segment expanded by 26.2% on an annual basis. The paints pack segment also experienced a growth of 10.82%, although the lubricant segment witnessed a decline in market demand.
Future Outlook and Management Commentary
Commenting on future expansion strategies, J Rana Pratap, Senior Vice President of Marketing and in-charge of the Pharma Business division, stated that there is a massive opportunity in pharma packaging, including diagnostics. He noted that the firm has concrete plans to enter high-margin areas such as dosage pens, while also examining ways to venture into electronics and semiconductor packaging to leverage its deep knowledge in mold making and robotics.
